The proposed therapy is a clinical phase II trial performed at MSKCC. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining colony-stimulating factors, such as sargramostim, with monoclonal antibodies may be an effective treatment for advanced neuroblastoma. It is a Phase II trial to study the effectiveness of monoclonal antibody 3F8 plus sargramostim in treating patients who have advanced neuroblastoma.
Dr. Kushner’s team ahs completed a study of this regimen with a monoclonal antobody and has a manuscript that is ready for submission. There are no publications yet available to assess this therapy.